Transplantation Proceedings
Volume 39, Issue 9 , Pages 2736-2739 , November 2007

Anticancer Effect of Sirolimus in Renal Allograft Recipients With De Novo Malignancies

  • M. Boratyńska

      Affiliations

    • Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland
    • Corresponding Author InformationAddress reprint requests to Maria Boratyńska, Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Traugutta 57/59, 50-417 Wroclaw, Poland.
    • ,
  • E. Wątorek

      Affiliations

    • Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland
    • ,
  • D. Smolska

      Affiliations

    • Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland
    • ,
  • D. Patrzałek

      Affiliations

    • Department of General, Vascular and Transplantation Surgery, Wroclaw Medical University, Wroclaw, Poland.
    • ,
  • M. Klinger

      Affiliations

    • Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland

References 

  1. Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin’s lymphoma. Cancer Treat Rev. 2007;33:78
  2. Vega F, Medeiros LJ, Leventaki V. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 2006;66:6589
  3. Luan FL, Ding R, Sharma VK. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int. 2003;63:917
  4. Mita MM, Mita A, Rovinsky EK. Mamalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer. 2003;4:126
  5. Campistol JM, Albanell J, Arns W. Use of proliferation signal inhibitors in the management of post-transplant malignacies-clinical guidance. Nephrol Dial Transplant. 2007;22(Suppl1):136
  6. Raymond E, Alexandre J, Faivre S. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336
  7. Ghobrial IM, Habermann TM, Maurer MJ. Prognostic analysis for survival in adults solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005;23:7574
  8. Stallone G, Schena A, Infante B. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317
  9. Campistol J, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a succesful treatment for posttransplantation Kaposi’s sarcoma. Transplantation. 2004;77:760
  10. Zmonarski S, Boratynska M, Rabczynski J. Regression of Kaposi’s sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc. 2005;37:964
  11. Sanches-Fructuoso A, Conesa J, Perez Florez I. Conversion to sirolimus in renal transplant patients. Transplant Proc. 2006;38:2451
  12. Jimenez-Rivera C, Avitzur Y, Fecteau A. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant. 2004;8:243
  13. Zaltzman J, Prasad R, Chun K. Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus. Nephrol Dial Transplant. 2005;20:1748
  14. Cullis B, D’Souza R, McCullagh P. Sirolimus induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis. 2006;47:E67
  15. Kahan BD, Yakupoglu YK, Schoenberg L. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation. 2005;80:749
  16. Koehl GE, Andrassy J, Guba M. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation. 2004;77:1319
  17. Guba M, Koehl GE, Neppl E. Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int. 2005;18:89

PII: S0041-1345(07)01067-6

doi: 10.1016/j.transproceed.2007.08.078

Transplantation Proceedings
Volume 39, Issue 9 , Pages 2736-2739 , November 2007

Article Tools